Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (401-410 of 607) with videos related to

Pageof 61
Sort By:
Arthritis and Rheumatism|February 14, 2012
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisP A Merkel, N P Silliman, P J Clements, et al.
The European Respiratory Journal|October 30, 2010
Increased epithelial permeability in pulmonary fibrosis in relation to disease progressionN S L Goh, S R Desai, C Anagnostopoulos, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2016
Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic SclerosisZoe E Betteridge, Felix Woodhead, Hui Lu, et al.
Annals of the Rheumatic Diseases|February 10, 2026
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosisMaithri Aspari, Voon Ong, Klaus Søndergaard, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|November 18, 2004
Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to sclerodermaA L Lagan, P Pantelidis, E A Renzoni, et al.
Arthritis Research & Therapy|June 1, 2022
Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trialEdward P Stern, Lauren V Host, Ivy Wanjiku, et al.
Arthritis Research & Therapy|December 10, 2025
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trialStefano Rodolfi, Kristina Clark, Bahja Ahmed Abdi, et al.
The International Journal of Biochemistry & Cell Biology|March 4, 2021
Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertensionAngela Y Y Tam, Amy L Horwell, Sarah L Trinder, et al.
Pageof 61

Showing results (401-410 of 607) with videos related to

Sort By:
Pageof 61
Arthritis and Rheumatism|February 14, 2012
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisP A Merkel, N P Silliman, P J Clements, et al.
The European Respiratory Journal|October 30, 2010
Increased epithelial permeability in pulmonary fibrosis in relation to disease progressionN S L Goh, S R Desai, C Anagnostopoulos, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2016
Brief Report: Anti-Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic SclerosisZoe E Betteridge, Felix Woodhead, Hui Lu, et al.
Annals of the Rheumatic Diseases|February 10, 2026
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosisMaithri Aspari, Voon Ong, Klaus Søndergaard, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|November 18, 2004
Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to sclerodermaA L Lagan, P Pantelidis, E A Renzoni, et al.
Arthritis Research & Therapy|June 1, 2022
Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trialEdward P Stern, Lauren V Host, Ivy Wanjiku, et al.
Arthritis Research & Therapy|December 10, 2025
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trialStefano Rodolfi, Kristina Clark, Bahja Ahmed Abdi, et al.
The International Journal of Biochemistry & Cell Biology|March 4, 2021
Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertensionAngela Y Y Tam, Amy L Horwell, Sarah L Trinder, et al.
Pageof 61